21 results
8-K
EX-99.1
NAMS
NewAmsterdam Pharma Company N.V.
7 Aug 24
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
8:00am
.”
"In addition, we recently hosted an R&D Day event where we detailed the differentiated target product profile of obicetrapib, discussed our … of this composition of matter patent provides intellectual property protection for obicetrapib until July 2043.
In May 2024, NewAmsterdam hosted an R&D Day
8-K
EX-99.1
NAMS
NewAmsterdam Pharma Company N.V.
9 May 24
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
8:00am
--
-- Company to host R&D event on May 16, 2024, beginning at 9:00 a.m. ET in New York City –
-- Strong financial position; ending the quarter … and commercial strategy at our R&D Day on May 16th and, if our Phase 3 program is successful and regulatory approval is received, to delivering obicetrapib
10-Q
2024 Q1
NAMS
NewAmsterdam Pharma Company N.V.
8 May 24
Quarterly report
4:30pm
ended March 31,
(In thousands of USD)
License revenue attributed from license performance obligation
License revenue attributed from R&D performance … obligation
Total revenue
All revenue recognized from the R&D performance obligation was included within deferred revenue on the consolidated balance
8-K
EX-99.1
NAMS
NewAmsterdam Pharma Company N.V.
28 Feb 24
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
8:11am
as revenue upon execution of the license agreement.
Research and Development (“R&D”) Expenses: R&D expenses were $159.4 million in the year ended
10-K
ky1 23p4el
28 Feb 24
Annual report
8:00am
424B3
1htcmj
13 Nov 23
Prospectus supplement
8:24am
6-K
91tldr1urlu9xzg
13 Nov 23
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights
12:00am
6-K
EX-99.1
hh4ijz0nfx z5tuc
13 Nov 23
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights
12:00am
424B3
tfdz9i6
15 Aug 23
Prospectus supplement
4:52pm
POS AM
ze9hb2
7 Aug 23
Prospectus update (post-effective amendment)
7:56am
6-K
EX-99.1
kq5o51lrd3w u1nl3
7 Aug 23
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights
7:38am
6-K
EX-99.1
4not5c0rzzan sse
7 Aug 23
Research and development expenses
7:24am
6-K
EX-99.2
l4p14 f4h
7 Aug 23
Research and development expenses
7:24am
424B3
fbk2z8q
8 Jun 23
Prospectus supplement
5:01pm
424B3
che60nxx arl9im
6 Jun 23
Prospectus supplement
4:20pm
424B3
qhmshbcd36d
25 Apr 23
Prospectus supplement
8:14am
POS AM
giyl0ky6z 3se6hldnsx
17 Apr 23
Prospectus update (post-effective amendment)
9:09am
F-1
8t2er56
19 Dec 22
Registration statement (foreign)
6:22pm